Skip to content
Preprint · OA via OpenAlex

Alpha-synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease

Tracy A. Cole, Hien Tran Zhao, Timothy J. Collier, Ivette M. Sandoval, Caryl E. Sortwell, Kathy Steece‐Collier, Brian F. Daley, Alix Booms, Jack W. Lipton, Mackenzie Welch, Melissa Berman, Luke Jandreski, Danielle L. Graham, Andreas Weihofen, Stephanie L. Celano

bioRxiv (Cold Spring Harbor Laboratory) · 2019 · ▲ 10 citations

Abstract

Abstract Parkinson’s disease (PD) is a prevalent neurodegenerative disease with no approved disease-modifying therapies. Multiplications, mutations, and single nucleotide polymorphisms in the SNCA gene, encoding alpha-synuclein protein (aSyn), either cause or increase risk for PD. Intracellular accumulations of aSyn are pathological hallmarks of PD. Taken together, reduction of aSyn production may provide a disease-modifying therapy for PD. We show that antisense oligonucleotides (ASOs) reduce production of aSyn in rodent pre-formed fibril (PFF) models of PD. Reduced aSyn production leads to prevention and removal of established aSyn pathology and prevents dopaminergic cell dysfunction. In addition, we address the translational potential of the approach through characterization of human SNCA targeting ASOs that efficiently suppress the human SNCA transcript in vivo. We demonstrate broad activity and distribution of the human SNCA ASOs throughout the non-human primate brain and a corresponding decrease in aSyn cerebral spinal fluid (CSF) levels. Taken together, these data suggest that by inhibiting production of aSyn it may be possible to reverse established pathology and thus supports the development of SNCA ASOs as a potentially disease modifying therapy for PD and related synucleinopathies. Summary Antisense oligonucleotides designed against SNCA , which are progressing to the clinic, have the potential to be a disease modifying therapeutic for Parkinson’s disease patients.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1101/830554
Canonical
link ↗
Fetched
2026-10-27 MST

Cite this

APA
Cole, T.A., Zhao, H.T., Collier, T.J., Sandoval, I.M., Sortwell, C.E., Steece‐Collier, K., Daley, B.F., Booms, A., Lipton, J.W., Welch, M., Berman, M., Jandreski, L., Graham, D.L., Weihofen, A., Celano, S.L., Schulz, E., Cole-Strauss, A., Luna, E., Quach, D., &amp; Mohan, A. (2019). Alpha-synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease. <em>bioRxiv (Cold Spring Harbor Laboratory)</em>. https://doi.org/10.1101/830554
Vancouver
Cole TA, Zhao HT, Collier TJ, Sandoval IM, Sortwell CE, Steece‐Collier K, et al. Alpha-synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease. bioRxiv (Cold Spring Harbor Laboratory). 2019. doi:10.1101/830554.
BibTeX
@unpublished{tracy2019Alphas, title = {Alpha-synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease}, author = {Tracy A. Cole and Hien Tran Zhao and Timothy J. Collier and Ivette M. Sandoval and Caryl E. Sortwell and Kathy Steece‐Collier and Brian F. Daley and Alix Booms and Jack W. Lipton and Mackenzie Welch and Melissa Berman and Luke Jandreski and Danielle L. Graham and Andreas Weihofen and Stephanie L. Celano and Emily Schulz and Allyson Cole-Strauss and Esteban Luna and Duc Quach and Apoorva Mohan and C. Frank Bennett and Eric E. Swayze and Holly B. Kordasiewicz and Kelvin C. Luk and Katrina L. Paumier}, journal = {bioRxiv (Cold Spring Harbor Laboratory)}, year = {2019}, doi = {10.1101/830554}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings